Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast)

Main Article Content

Brad Glick
Edward Lain
Tina Lin
Robert Israel

Keywords

psoriasis, tazarotene, halobetasol

Abstract

Abstract not available.

References

1. Menter, et al. J Am Acad Dermatol. 2009;60(4):643-659.

2. Gold LS, et al. J Am Acad Dermatol. 2018;79(2):287-293.

3. Sugarman JL, et al. J Drugs Dermatol. 2018;17(8):855-861.

4. Kircik LH, et al. J Drugs Dermatol. 2019;18(3):279-284.

5. Strober B, et al. J Drugs Dermatol. 2017;16(8):801-808.